Novartis’ Rhapsido (remibrutinib) wins FDA approval for symptomatic dermographism

The significance lies less in the drug's novelty than in the regulatory path: an oral BTK inhibitor already cleared for CSU now extends into a second mast-cell-driven skin condition, reinforcing a franchise rather than a one-off approval. For patients with SD inadequately controlled on antihistamines, this is the first labeled option, which shifts the treatment conversation from off-label guesswork to a defined standard. The open question is whether payers treat SD as a distinct indication or fold it into existing CSU coverage criteria, and how broadly the label's controlled-population language is read in practice.